Celsius Therapeutics Announces Executive Leadership Team Appointments

Greg Ryslik, Ph.D., Appointed to Chief Data Officer

Michael Boretti, Ph.D., Appointed to Chief Business Officer

CAMBRIDGE, Mass.–(BUSINESS WIRE)–Celsius Therapeutics, a company translating single-cell genomic insights
into precision therapeutics for patients with autoimmune diseases and
cancer, today announced its first key leadership appointments. Greg
Ryslik, Ph.D., has joined as chief data officer, and Michael Boretti,
Ph.D., has joined as chief business officer.

“Over the past year, we have been building our team and assembling an
integrated, industrial-scale platform that combines single-cell
genomics, machine learning, deep biology and drug discovery, which has
enabled Celsius to advance its understanding of the specific cells and
genetic drivers that could play a key role in autoimmune diseases and
cancer,” said Alexis Borisy, chairman of Celsius. “Greg’s demonstrated
leadership in applying machine learning to extract unique insights
across a spectrum of large, complex datasets will add more power to our
target and drug discovery engine, while Mike’s range of experiences,
including leading corporate strategy development and partnership
formation, will be instrumental to maximizing the value and impact of
our platform and pipeline.”

Dr. Ryslik is a statistician, data scientist and artificial intelligence
researcher with experience building and leading data initiatives in
companies ranging across the biotech, autotech, healthtech and fintech
domains. Prior to Celsius, he was vice president of data science at
Mindstrong Health, a healthcare company transforming mental health
treatment through measurement science and artificial intelligence.
Previously, Dr. Ryslik was the senior director and head of data science
at Faraday Future, an electric vehicle startup in Los Angeles as well as
the leader of the service data science group at Tesla Motors in Palo
Alto. Earlier in his career, he performed machine learning research and
nonclinical biostatistics research at Genentech. Concurrently, Dr.
Ryslik holds an adjunct assistant professor position at Pennsylvania
State University and has lectured on statistics for artificial
intelligence, machine learning at Stanford University Continuing
Studies. He holds a Ph.D. from Yale University in biostatistics, where
he researched oncogenic mutation clustering embedded within protein
structure. He also holds a master’s degree in statistics from Columbia
University and an undergraduate degree in mathematics, computer science
and finance from Rutgers University.

Dr. Boretti brings to Celsius Therapeutics nearly 15 years of experience
in the biotechnology industry, including leadership roles encompassing
business development, strategic planning, and program and alliance
management. He has a strong track record of planning, negotiating and
implementing strategic alliances across a wide range of collaboration
structures. He joins Celsius from Epizyme, where he was vice president
of business development and responsible for the formation new
partnerships, including key collaborations with Boehringer Ingelheim and
Roche, while also overseeing management of numerous other strategic
alliances. Prior to Epizyme, Dr. Boretti worked in roles of increasing
responsibility at AVEO Oncology, most recently serving as vice
president, corporate development and alliance management, where he drove
the formation of partnerships around many of AVEO’s clinical- and
discovery-stage programs, including significant transactions with
Novartis, Janssen and Astellas. Prior to AVEO, Dr. Boretti was a
consultant in the life sciences practice at L.E.K. Consulting, a global
strategic consulting firm. He holds an undergraduate degree in
engineering science from the University of Virginia and a Ph.D. in
bioengineering from the University of Pennsylvania.

About Celsius Therapeutics

Celsius Therapeutics is charting a new course of target and drug
discovery by applying a systematic approach to single-cell sequencing of
patient tissue, combining massive datasets, complex algorithms, and
machine learning to discover first-in-class precision therapies with a
transformative impact on the lives of patients with autoimmune diseases
and cancer. Celsius was launched in 2018, is backed by Third Rock
Ventures and GV (formerly Google Ventures), and is based in Cambridge,
Mass. For more information, please visit www.celsiustx.com.

Contacts

Katie Engleman
1AB
[email protected]